Beijing Tide Pharmaceutical Co. Ltd. has described orydalmine derivatives reported to be useful for the treatment of pain, depression, and substance abuse and dependence.
Impact Therapeutics (Shanghai) Inc. has disclosed ubiquitin carboxyl-terminal hydrolase 1 (USP1) inhibitors reported to be useful for the treatment of cancer.
Shanghai Aryl Pharmtech Co. Ltd. and Zhejiang Hisun Pharmaceutical Co. Ltd. have presented compounds reported to be useful for the treatment of gram-negative bacterial infections.
A pair of co-published filings from Naples, Fla.-based Aerwave Medical Inc. describe apparatus and ultrasound-based methods for bronchial denervation, ablating smooth muscle or goblet cells, and emphysematous tissue remodeling in the treatment of respiratory conditions such as asthma and chronic obstructive pulmonary disease.
Arvinas Operations Inc. has synthesized proteolysis targeting chimera (PROTACs) compounds comprising an E3 ubiquitin ligase-binding moiety coupled to a B-cell lymphoma 6 protein (BCL6)-targeting moiety through a linker.
Merck Sharp & Dohme LLC has patented potassium voltage-gated channel subfamily C member 1 (Kv3.1; KCNC1) activators reported to be useful for the treatment of neurological and psychiatric disorders.